Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Clinical utility shown for Avantís mTOR assay
September 2017
SHARING OPTIONS:

GAITHERSBURG, Md.—Independent published data was published this quarter validating Avant Diagnostics Inc.’s proprietary Theralink mTOR phosphoprotein assay in delineating the estrogen receptor positive (ER+) breast cancer (BC) population by mTOR activation status. The data showed that ER+ BC patients with tumors that have a highly activated mTOR pathway were likely to have treatment resistance when treated with anti-endocrine therapies, while those with low levels of mTOR pathway activation are more likely to respond to such therapies.
 
Dr. Emanuel Petricoin, co-director of the Center for Applied Proteomics and Molecular Medicine at George Mason University, commented that “The data provides a strong rationale for physicians to seek out mTOR pathway activation status as measured by protein phosphorylation of specific mTOR kinase substrates as part of the standard biomarker profiling paradigm in this patient population.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.